Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

Table 4 Events during or within 24 hours of each rituximab infusion

Events	Infusion 1 (N = 351) n (%)(95% CI)^a	Infusion 2 (N = 337) n (%)(95% CI)^a	Infusion 3 (N = 289) n (%)(95% CI)^a	Infusion 4 (N = 278) n (%)(95% CI)^a
Serious IRRs	0 (0) (- to 0.8)	0 (0) (- to 0.9)	0 (0) (- to 1.0)	0 (0) (- to 1.1)
IRRs and other AEs	62 (17.7) (13.8 to 22.1)	24 (7.1) (4.6 to 10.4)	22 (7.6) (4.8 to 11.3)	5 (1.8) (0.6 to 4.1)
Serious AEs	0 (0) (- to 0.8)	0 (0) (- to 0.9)	0 (0) (- to 1.0)	0 (0) (- to 1.1)
CTC grade 3/4 AEs	2 (0.6) (0.1 to 2.0)	2 (0.6) (0.1 to 2.0)	0 (0) (0.1 to 2.1)	0 (0) (0.0 to 1.3)
Infusion stopped/slowed/interrupted^b	43 (12.3) (9.0 to 16.1)	13 (3.9) (2.1 to 6.5)	19 (6.6) (4.0 to 10.1)	3 (1.1) (0.2 to 3.1)

AE, adverse event; CTC, Common Terminology Criteria; IRRs, infusion-related reactions. ^aOne-sided CI for serious events. ^bDue to AE, medication error, or other reason such as bathroom break.

ISSN: 1471-2474